U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB / A
(Amendment No. 2)
(MARK ONE)
[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 (fee required)
For the fiscal year ended December 31, 1998
[ ] TRANSITION REPORT UNDER SECTION 13 OR A5(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 (no fee required)
Commission file number 0-23544
-------
HUMAN PHEROMONE SCIENCES, INC.
----------------------------------------------
(Name of small business issuer in its charter)
California 94-3107202
- ------------------------------- -------------------
(State or other jurisdiction of (I.R.S. employee
incorporation or organization) Identification No.)
4034 Clipper Court, Fremont, California 94538
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip code)
Issuer's telephone number: (510) 226-6874
--------------
Securities registered under Section 12(b) of the Exchange Act:
None
----------------
(Title of class)
Check whether the Issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes [ X ] No [ ]
Check if there is no disclosure of delinquent filers in response to
Item 405 of Regulation S-B contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [ X ]
State issuer's revenues for its most recent fiscal year. $10,378,717
------------
State the aggregate market value of the voting stock held by
non-affiliates computed by reference to the price at which the stock was sold,
or the average bid and asked price of such stock, as of a specified date within
the past 60 days. (See definition of affiliate in rule 12b-2 of the Exchange
Act.) $5,734,481 (1)
----------
(1) Excludes 473,921 shares held by directors, officers and shareholders whose
ownership exceeds 5% of the outstanding shares at June 11, 1999 based on a
closing bid price on that day of $1.94 per share. Exclusion of such shares
should not be construed as indicating that the holders thereof possess the
power, direct or indirect, to direct the management or policies of the
registrant or that such person is controlled by or under common control with the
registrant.
(APPLICABLE ONLY TO CORPORATE REGISTRANTS)
State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date. 479,778 shares of
convertible preferred stock, 3,429,839 shares of common stock as of June 11,
1999.
Transitional Small Business Disclosure Format (check one):
Yes [ ] No [X]
1
<PAGE>
Item 13. Exhibits and Reports on Form 8-K
EXHIBIT
NUMBER EXHIBIT TITLE
------ -------------
10.17 Supply Agreement with Avon Products, Inc.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
HPSI Corporation has duly caused this Amendment to the Annual Report on Form
10-KSB to be signed on its behalf by the undersigned, thereunto duly authorized,
in Fremont, California, on June 30, 1999
HPSI CORPORATION
By: /s/ William P. Horgan
---------------------------------
Name: William P. Horgan
---------------------------------
Title: Chairman of the Board
---------------------------------
<TABLE>
Pursuant to the requirements of the Securities Exchange Act of 1934,
this Amended Annual Report has been signed on behalf of Human Pheromone
Sciences, Inc. by the following persons in the capacities and on the dates
indicated.
<CAPTION>
SIGNATURE CAPACITY DATE
--------- -------- ----
<S> <C> <C>
/s/ William P. Horgan Chief Executive Officer June 30, 1999
- -------------------------------------- and Director
William P. Horgan
/s/ Gregory S. Fredrick Vice President, June 30, 1999
- -------------------------------------- Principal Financial and
Gregory S. Fredrick Accounting Officer
/s/ Bernard I. Grosser Director June 30, 1999
- --------------------------------------
Bernard I. Grosser, MD
/s/ Michael D. Kaufman Director June 30, 1999
- --------------------------------------
Michael D. Kaufman
/s/ Helen C. Leong Director June 30, 1999
- --------------------------------------
Helen C. Leong
/s/ Robert Marx Director June 30, 1999
- --------------------------------------
Robert Marx
</TABLE>
3
THE SYMBOL '*' IS USED THROUGHOUT THIS EXHIBIT TO INDICATE THAT A PORTION OF THE
EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
SUPPLY AGREEMENT
THIS AGREEMENT is entered into this 15th day of December, 1998 between
HUMAN PHEROMONE SCIENCES, INC., a corporation, with an office at 4034 Clipper
Court, Fremont, California 94538 (hereinafter referred to as "HPSI"), and AVON
PRODUCTS, INC., a New York corporation, with an office at 1345 Avenue of the
Americas, New York, New York 10105 (hereinafter referred to as "AVON").
WHEREAS, HPSI represents that it owns patent rights relating to the use
of certain human pheromones;
WHEREAS, AVON is interested in developing a business relationship with
HPSI for the manufacture, supply, sale and distribution of a global line of
products containing such human pheromones;
NOW, THEREFORE, in consideration of the foregoing promises and mutual
covenants hereinafter contained, the parties hereby agree as follows:
ARTICLE I.
DEFINITIONS
The following terms shall have the respective meanings hereinafter
indicated:
(a) "Affiliate" shall mean (i) any person, firm or company of which
AVON now or hereafter owns or controls, directly or indirectly, forty percent
(40%) or more, or (ii) any person, firm or company which now or hereafter owns
or controls, directly or indirectly, forty percent (40%) or more of AVON, or
(iii) any person, firm or company which is under common control with AVON. For
the purpose of this definition, where ownership is by stock ownership, the stock
owned or controlled by a particular person, firm or company shall be deemed to
include all stock owned or controlled, directly or indirectly, by any other
person, firm or company of which the particular person, firm or company owns or
controls, directly or indirectly, forty percent (40%) or more of the stock
having the right to vote for directors thereof.
(b) "Effective Date" shall mean January 1, 1999.
(c) "Field of Use" shall mean the global market served by AVON,
including, but not limited to: (i) the market serviced by a distribution system
utilizing a sales force of independent sales representatives selling the
Products (as hereafter defined) primarily
1
<PAGE>
to the general public; (ii) catalogs and direct mail; (iii) direct
telecommunications sales, including, without limitation, sales by means of
radio, television, telephone, the Internet or on-line computer services; and
(iv) any retail outlet (including, without limitation, the Avon Centre, Avon
Sales Centers, Avon Beauty Centers, Avon Express Centers, mall carts and kiosks)
where primarily AVON products are sold. Field of Use shall expressly exclude
mass merchandisers and drug chains/stores in the United States and Canada.
(d) "Patents" shall mean United States Patent Nos. 5,272,134 and
5,278,141 and all divisions, continuations, and continuation-in-part
applications, reissues and re-examinations thereof and patents issuing
therefrom, and all corresponding foreign patent applications and granted foreign
parents.
(e) "Pheromone(s)" shall mean the steroid(s), [*] and [*] referred to
in the claims of the Patents which will be at the [*]of [*] of [*] and [*] of
[*].
(f) "Product(s)" shall mean fragrances and fragrance ancillary products
(such as lotions, creams, shower gel, talc, body products, bath preparations,
bath products and bath soaps), fragrances for inclusion in home scents, candles
and room sprays, all of which use a Pheromone as a component. Notwithstanding
the foregoing, in no event shall Products include any product for which a claim
is made that such product may be used for the cure, prevention, treatment,
mitigation or diagnosis of any disease. Nothing shall prevent AVON from making
any other types of substantiated claims for these Products.
(g) "Quest" shall mean Quest International, the fragrance company that
will purchase the Pheromones from HPSI on AVON's behalf.
(h) "Specifications" shall mean Pheromones with the characteristics set
forth by AVON.
(i) "Technical Information" shall mean any and all information,
including manufacturing information, trade secrets, data, expertise and
know-how, known by HPSI and relating to the use of pheromones.
ARTICLE II.
SUPPLY OF PHEROMONES
2.1. Purchase and Sale of Pheromones: During the term of this
Agreement, HPSI shall provide to AVON, and Quest will purchase from HPSI on
AVON's behalf, for sale only to Avon and its Affiliates and not to any other
party or to be used by Quest or any other party, all of AVON's requirements of
the Pheromones for inclusion in Products to be sold on a non-exclusive basis in
the Field of Use. It is understood by the parties that, upon Quest's payment to
HPSI for the supply of Pheromones or to any third party as
2
<PAGE>
set forth in 2.6, it is agreed that neither Quest nor any third party having
rights under the Patents will bring any claim or action against AVON or any of
its Affiliates based on or asserting that the use, sale or offer for sale or
import of Products in the Field of Use violates any proprietary or patent rights
of HPSI.
2.2. Placement of Orders by Quest: Quest will submit firm purchase
orders on AVON's behalf to HPSI from time to time specifying the quantity of
Pheromones desired and the shipment date of dates for the quantity (or specific
quantities, if more than one shipment date is specified) of the Pheromones set
forth in the purchase order. The shipping date shall not be less than ninety
(90) days after the date of the written purchase order. Prior to placing any
orders with HPSI, Quest shall be required to sign a confidentiality agreement
which will govern the use by Quest of the Technical Information provided by
HPSI.
2.3. Specifications: HPSI will supply the Pheromones in accordance with
AVON's Specifications, a copy of which will be attached and incorporated herein.
2.4. Delivery of the Pheromones: HPSI will deliver the quantities of
the Pheromones as set forth in each Quest purchase order. The Pheromones shall
be shipped F.O.B. Salt Lake City to Quest International, 400 International
Drive, Mt. Olive, New Jersey 97828, Attention: Neil Wasser. Quest will specify
to HPSI the method of shipment. AVON shall be solely responsible for payment of
all delivery costs to Quest. HPSI will deliver [*] of Pheromones to Quest no
later than [*]. HPSI will send [*] of Pheromones to Quest no later than [*].
HPSI agrees to deliver [*] additional [*] of Pheromones to Quest no later than
[*]. HPSI agrees to keep a one (1) pound minimum quantity of Pheromones in
inventory at all times during the term of this Agreement for sale to AVON. HPSI
will also deliver [*] of [*] and [*] of [*] to AVON's Research & Development
facility within seven days of signing this Agreement.
2.5. Guarantee: HPSI shall provide AVON with a certificate for each
shipment of Pheromones representing, warranting and guaranteeing that, at the
time of delivery of the Pheromones to Quest, such Pheromones (i) will have been
manufactured, packaged, held and shipped in accordance with AVON's
Specifications and (ii) will have expiration dating of not less than [*] after
the date of delivery thereof. HPSI shall retain a sufficient quantity of
retention samples of each lot of the Pheromones that are shipped to Quest
throughout the term of this Agreement.
2.6. Notification: In the event that HPSI, at any time during the term
of this Agreement, shall have reason to believe that it will be unable to timely
supply Quest with the full quantity of the Pheromones ordered by Quest, HPSI
shall promptly notify AVON thereof. In the event it is determined that HPSI will
be unable to completely fulfill its commitment to supply AVON's required amount
of Pheromones, HPSI shall fully cooperate with AVON in locating third party
supplier(s) and permit such third party
3
<PAGE>
supplier(s) to complete AVON's supply requirement of Pheromones. In such event,
HPSI agrees to disclose to the third party supplier(s), pursuant to a
confidentiality agreement, all Technical Information necessary to enable the
third party supplier(s) to complete such supply. Any consideration paid by AVON
to such third party supplier(s) shall be taken as a credit by AVON against the
supply fees due to HPSI under this Agreement. Compliance by HPSI with this
Section 2.7 shall not relieve HPSI of any other obligation or liability under
this Agreement, including without limitation any provision of this Section 2.
ARTICLE III.
SUPPLY FEES
3.1. Fee: The fee to be paid for the Pheromones is [*] in crystallized
form. This fee shall remain firm through December 31, 2001.
3.2. Invoicing by Quest: HPSI will invoice Quest for each quantity of
Pheromones on or after the date on which HPSI ships such quantity to Quest. All
invoices from HPSI to Quest will be due in full thirty (30) days after the date
of invoice. In the event that Quest does not make payment to HPSI, AVON shall be
obligated to make such payment to HPSI forthwith.
ARTICLE IV.
REPRESENTATIONS AND WARRANTIES
4.1. HPSI covenants, represents and warrants:
(a) That it is the exclusive owner of all rights in and to all
the Patents;
(b) That, to the best of its knowledge, there are no (i)
facts, claims or threats that would adversely affect AVON's ability to use or
sell the Pheromones in the Products or (ii) other person(s), firm(s),
corporation(s) or other entity having any right, title or interest in, any or
all of the Patents in the Field of Use;
(c) That it has full power to grant the rights, and privileges
herein given;
(d) That HPSI has the expertise, facilities and personnel
necessary to manufacture the Pheromones in a timely manner in accordance with
the terms and conditions of this Agreement.
(e) That the Pheromones are produced from materials meeting
all of AVON Specifications.
4
<PAGE>
(f) Except as otherwise set forth in Sections 4.1 and 2.5,
HPSI makes no warranty or representation, express or implied, including but not
limited to any warranty of merchantability or fitness for any particular
purpose.
ARTICLE V.
TERM
5.1. The term of this Agreement shall begin on the Effective Date and
will expire on December 31, 2001. This Agreement may be renewed by mutual
agreement for one or more successive renewal terms, provided that such agreement
is reached at least thirty (30) days before the expiration of the initial term
or any renewal term.
5.2. AVON shall have the right to terminate this Agreement at any time
upon ninety (90) days prior written notice to HPSI. In the event of any such
termination of this Agreement, AVON shall continue to have the right to use and
sell the Products until such time as AVON completely consumes its remaining
inventory of Products. Termination of this Agreement shall not relieve AVON of
any requirement to make any payment that has accrued prior to such termination.
ARTICLE VI.
INDEMNIFICATION
6.1. Notwithstanding anything to the contrary contained or suggested
herein, HPSI agrees to indemnify and hold harmless AVON from and against any and
all claims, damages and liabilities asserted by any third party for any finders
fee(s), commission(s) or the like arising from or out of any claim made by such
third party in connection with this Agreement or the subject matter hereof.
ARTICLE VII.
MISCELLANEOUS
7.1. Assignability: Neither this Agreement nor any license or right
hereunder shall be assignable or otherwise transferable by either party hereto,
except to a successor to substantially all of the business to which this
Agreement relates, provided that such successor shall expressly assume all of
the obligations and liabilities of the assigning party hereunder.
7.2. Bankruptcy: This Agreement may be terminated by either party if
the other party makes an assignment for the benefit of creditors, files a
petition in bankruptcy, petitions or applies to any tribunal for the appointment
of a custodian, receiver, trustee or similar official for it or a substantial
part of its assets, or commences any case or proceeding under any bankruptcy,
reorganization, arrangement, readjustment of debt,
5
<PAGE>
dissolution or liquidation law or statute of any jurisdiction, whether now or
hereafter in effect; or if any such petition or application is filed or any such
case or proceeding is commenced against the other party, in which an order for
relief is entered or which remains undismissed for a period of sixty (60) days
or more; or if by any act or omission the other party indicates its consent to,
approval of or acquiescence in any such petition, application or a case or
proceeding or order for relief or the appointment of a custodian, receiver or
any trustee or similar official for it or any substantial part of any of its
assets, or suffers any such custodianship, receivership, trusteeship or
jurisdiction of a similar official to continue undischarged for a period of
sixty (60) days or more.
7.3. Avon Independent Contractors: Notwithstanding anything to the
contrary contained in this Agreement, it is understood that Avon's Sales
Representatives are independent contractors who are not under Avon's control,
and Avon shall not be responsible in any way for any sales by such
Representatives which, if undertaken by Avon itself, would be in violation of
this Agreement.
7.4. Force Majeure: Neither party shall be liable for delay in
performance, or nonperformance caused by circumstances beyond the reasonable
control of the party affected, including, but not limited to, acts of God, fire,
floods, acts of war or violence, labor disputes or shortages, plant shutdown,
governmental actions, or inability to obtain materials, equipment or
transportation.
7.5. Governing Law: This Agreement shall be deemed to have been made
and executed in the State of New York, and its form, execution, validity and
construction shall be determined in accordance with the laws of that State,
without giving any effect to any conflict of laws provisions.
7.6. Modifications: This Agreement including the Attachments hereto
comprise the entire understanding of the parties with respect to the subject
matter hereof, and each party agrees, upon the request of the other, to execute
and deliver such documents and take such actions as may be reasonably requested
in order to carry out the intent and purposes of this Agreement. No amendment to
or modification of this Agreement shall be valid or binding upon a party hereto
unless signed by a duly authorized signatory of the party claimed to be bound
thereby.
7.7. Notices: Any notice or request expressly provided for under this
Agreement shall be in writing, shall be given either manually or by mail or
facsimile, and shall be deemed sufficiently given if and when received by the
party to be notified at its address set forth below or, if and when mailed by
registered mail, postage prepaid, addressed to such party at such address.
Notices to AVON shall be addressed to:
Avon Products, Inc.
1251 Avenue of the Americas
6
<PAGE>
New York, New York 10020
Attention: Donna Edbril, Esq.
Notice to HPSI shall be addressed to:
Chief Executive Officer
Human Pheromone Sciences, Inc.
3034 Clipper Court
Fremont, California 94538
With a Copy to:
Heller Ehrman White & McAuliffe
525 University Avenue
Palo Alto, California 94301
Attention: Julian N. Stern
Either party may, by notice to the other, change its address for
receiving such notices and requests.
7.8. Publicity: HPSI agrees that it shall not issue any press
release(s) or make any other public statement(s) with respect to the existence
of and/or the term and/or conditions of this Agreement or the relationship of
the parties, without the prior written consent of AVON provided that, subject to
AVON's reasonable review and approval, HPSI may issue any press release(s) or
other public statements that its legal counsel reasonably determines to be
legally advisable or is required by law or regulation.
7.9. No Waiver: The waiver of any breach of this Agreement by either
party hereto shall in no event constitute a waiver as to any future breach,
whether similar or dissimilar in nature.
7.10. Partial Invalidity: Invalidity of any part of this Agreement
under applicable governing law shall not invalidate any other part or parts
hereof which are otherwise valid under applicable governing law. In the event
that any provision(s), term(s) and/or condition(s) herein are determined to be
invalid or partially invalid under applicable governing law, the parties shall
thereupon negotiate in good faith to amend this Agreement so as to comply with
applicable governing law.
7
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first set forth above.
AVON PRODUCTS, INC. HUMAN PHEROMONES SCIENCES, INC.
By: /s/ Terry Burstein By: /s/ William P. Horgan
------------------------------------ -------------------------------
Name: Terry Burstein Name: William P. Horgan
---------------------------------- -----------------------------
Title: Director Global Fragrances Title: Chairman, CEO
---------------------------------- -----------------------------
8
